EndocrinologyHigh Prevalence of Endogenous Hypercortisolism in Patients With Type 2 Diabetes and Resistant Hypertension: Results From the MOMENTUM StudyUmpierrez et al. • 2026 • ADA June 8, 2026
EndocrinologyEffects of Mifepristone in People With Difficult-to-Control T2D and Hypercortisolism on GLP-1 RAsSloan et al. • 2026 • ADA June 6, 2026
OncologySYNERGY: A Phase 1b/2 Study of Nenocorilant, a Selective Glucocorticoid Receptor Antagonist, Plus Nivolumab in Patients With Advanced Solid MalignanciesHamid et al. • 2026 • ASCO May 30, 2026
OncologyTRIDENT: A Phase 2 Study of Relacorilant Plus Nab-paclitaxel and Gemcitabine in Chemotherapy-naïve Patients With Metastatic Pancreatic Ductal AdenocarcinomaBorazanci et al. • 2026 • ASCO May 30, 2026
OncologyOverall Survival Subgroup Analyses for Prior Taxane Use in the Phase 3 ROSELLA Trial of Relacorilant Plus Nab-Paclitaxel vs Nab-Paclitaxel Monotherapy in Patients With Platinum-Resistant Ovarian CancerGilbert et al. • 2026 • ASCO May 29, 2026
OncologySignaling Under Stress: Targeting the Glucocorticoid Receptor in CancerFlint et al. • 2026 • Cancer Res May 27, 2026
EndocrinologyCo-secretion of Cortisol and Aldosterone in Individuals With Resistant Hypertension: Results From the MOMENTUM TrialSloan et al. • 2026 • AACE April 24, 2026
EndocrinologyRelacorilant Treatment Improves Glycemic Control Among Individuals With Cushing Syndrome (Endogenous Hypercortisolism) and Hyperglycemia on Glucagon-Like Peptide-1 Receptor Agonists: Insights From a Phase 3 StudySilverstein et al. • 2026 • AACE April 24, 2026
OncologyReal-World Comparative Effectiveness of Nab-Paclitaxel and Paclitaxel in Combination with Bevacizumab in Patients with Platinum-Resistant Ovarian Cancer (COMPASS)Coleman et al. • 2026 • SGO April 13, 2026
OncologyRelacorilant Plus Nab-Paclitaxel Demonstrates a Progression-Free Survival Benefit in Ovarian Cancer Independent of Tumor Glucocorticoid Receptor (GR) Expression LevelsLorusso et al. • 2026 • SGO April 13, 2026
